• 1
    McQueen MJ, Hawken S, Wang X et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case–control study. Lancet 2008; 372: 22433.
  • 2
    National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143421.
  • 3
    Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 202633.
  • 4
    Talmud PJ, Hawe E, Miller GJ, Humphries SE. Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol 2002; 22: 191823.
  • 5
    Lamarche B, Moorjani S, Lupien PJ et al. Apolipoprotein A-I and B levels and the risk of ischaemic heart disease during a five year follow up of men in the Quebec cardiovascular study. Circulation 1996; 94: 2738.
  • 6
    Benn M, Nordestgaard BG, Jensen GB, Tybjaerg-Hansen A. Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B The Copenhagen City Heart Study. Arterioscler Thromb Vasc Biol 2007; 27: 66170.
  • 7
    Contois JH, McConnell JP, Sethi AA et al. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem 2009; 55: 40719.
  • 8
    Brunzell JD, Davidson M, Furberg CD et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2008; 51: 151224.
  • 9
    Sniderman A. Targets for LDL-lowering therapy. Curr Opin Lipidol 2009; 20: 2827.
  • 10
    Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med 2004; 255: 188205.
  • 11
    Barter PJ, Ballantyne CM, Carmena R et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med 2006; 259: 24758.
  • 12
    Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 2005; 294: 32633.
  • 13
    Kastelein JJ, van der Steeg WA, Holme I et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 2008; 117: 30029.
  • 14
    van der Steeg WA, Boekholdt SM, Stein EA et al. Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case–control analysis in EPIC-Norfolk. Ann Intern Med 2007; 146: 6408.
  • 15
    Pischon T, Girman CJ, Sacks FM et al. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 2005; 112: 337583.
  • 16
    Parish S, Peto R, Palmer A et al. The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls. Eur Heart J 2009; 30: 213746.
  • 17
    The Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302: 19932000.
  • 18
    Hillege HL, Fidler V, Diercks GF et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 177782.
  • 19
    Arnlöv J, Evans JC, Meigs JB et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 2005; 112: 96975.
  • 20
    Lambers Heerspink HJ, Brantsma AH, de Zeeuw D et al. Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality. Am J Epidemiol 2008; 168: 897905.
  • 21
    Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 256072.
  • 22
    Borggreve SE, Hillege HL, Wolffenbuttel BHR et al. An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study. J Clin Endocrinol Metab 2006; 91: 33828.
  • 23
    Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of diabetes mellitus. Diabetes Care 1997; 20: 118397.
  • 24
    Warnick GR, Nauck M, Rifai N. Evolution of methods for measurement of HDL-cholesterol: from ultracentrifugation to homogeneous assays. Clin Chem 2001; 47: 157996.
  • 25
    Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499502.
  • 26
    Steinmetz J, Tarallo P, Fournier B, Caces E, Siest G. Reference limits of apolipoprotein A-I and apolipoprotein B using an IFCC standardized immunonephelometric method. Eur J Clin Chem Clin Biochem 1995; 33: 33742.
  • 27
    Dullaart RPF, Groener JE, van Wijk H, Sluiter WJ, Erkelens DW. Alimentary lipemia-induced redistribution of cholesteryl ester between lipoproteins. Studies in normolipidemic, combined hyperlipidemic, and hypercholesterolemic men. Arteriosclerosis 1989; 9: 61422.
  • 28
    Birjmohun RS, Dallinga-Thie GM, Kuivenhoven JA et al. Apolipoprotein A-II is inversely associated with risk of future coronary artery disease. Circulation 2007; 116: 202935.
  • 29
    Sweetnam PM, Bolton CH, Downs LG et al. Apolipoproteins A-I, A-II and B, lipoprotein(a) and the risk of ischaemic heart disease: the Caerphilly study. Eur J Clin Invest 2000; 30: 94756.
  • 30
    Stehouwer CD, Smulders YM. Microalbuminuria and risk for cardiovascular disease: analysis of potential mechanisms. J Am Soc Nephrol 2006; 17: 210611.
  • 31
    Brantsma AH, Bakker SJ, Hillege HL et al. Urinary albumin excretion and its relation with C-reactive protein and the metabolic syndrome in the prediction of type 2 diabetes. Diabetes Care 2005; 28: 252530.
  • 32
    Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 1989; 32: 21926.
  • 33
    Stuveling EM, Bakker SJ, Hillege HL et al. C-reactive protein modifies the relationship between blood pressure and microalbuminuria. Hypertension 2004; 43: 7916.
  • 34
    Kshirsagar AV, Bomback AS, Bang H et al. Association of C-reactive protein and microalbuminuria (from the National Health and Nutrition Examination Surveys, 1999 to 2004). Am J Cardiol 2008; 101: 4016.
  • 35
    de Boer IH, Astor BC, Kramer H et al. Mild elevations of urine albumin excretion are associated with atherogenic lipoprotein abnormalities in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2008; 197: 40714.
  • 36
    Schmidt MI, Duncan BB. Diabesity: an inflammatory metabolic condition. Clin Chem Lab Med 2003; 41: 112030.
  • 37
    Dullaart RPF, de Vries R, Sluiter WJ, Voorbij HA. High plasma C-reactive protein (CRP) is related to low paraoxonase-I (PON-I) activity independently of high leptin and low adiponectin in type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2009; 70: 2216.
  • 38
    Dullaart RPF, de Vries R, Dikkeschei LD, Sluiter WJ. Higher plasma leptin largely explains increased C-reactive protein levels in women. Eur J Clin Invest 2007; 37: 2313.
  • 39
    Williams KJ, Tabas I. The response-to-retention hypothesis of atherogenesis reinforced. Curr Opin Lipidol 1998; 9: 4714.
  • 40
    van der Steeg WA, Holme I, Boekholdt SM et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol 2008; 51: 63442.
  • 41
    Dullaart RPF, Perton F, van der Klauw MM, Hillege HL, Sluiter WJ; on behalf of the PREVEND Study Group. High plasma lecithin:cholesterol acyltransferase activity does not predict low incidence of cardiovascular events: possible attenuation of cardioprotection associated with high HDL cholesterol. Atherosclerosis 2010; 208: 53742.
  • 42
    Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 2006; 58: 34274.
  • 43
    Corsetti JP, Gansevoort RT, Sparks CE, Dullaart RPF. Inflammation reduces HDL protection against primary cardiac risk. Eur J Clin Invest 2010; 40: 4839.
  • 44
    Dullaart RPF. Increased coronary heart disease risk determined by high high-density lipoprotein cholesterol and C-reactive protein: modulation by variation in the CETP gene. Arterioscler Thromb Vasc Biol 2010; 30: 15023.
  • 45
    Shao B, Oda MN, Oram JF, Heinecke JW. Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein. Curr Opin Cardiol 2006; 21: 3228.
  • 46
    Ballantyne CM, Raichlen JS, Cain VA. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial. J Am Coll Cardiol 2008; 52: 62632.
  • 47
    Kappelle PJWH, Zwang L, Huisman MV et al. Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein. Expert Opin Ther Targets 2009; 13: 74351.
  • 48
    Berkwits M, Guallar E. Risk factors, risk prediction, and the apolipoprotein B-apolipoprotein A-I ratio. Ann Intern Med 2007; 146: 6779.
  • 49
    Ware JH. The limitations of risk factors as prognostic tools. N Engl J Med 2006; 355: 26157.